Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Amicus Therapeutics Inc FOLD

Healthcare Biotechnology
Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.


NDAQ:FOLD - Post by User

Amicus Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(200)
•••
Post by whytestockson Aug 08, 2024 3:32pm
13 Views
Post# 36170032

Amicus Therapeutics Announces Second Quarter 2024 Financial

Amicus Therapeutics Announces Second Quarter 2024 Financial
News; $FOLD Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate UpdatesQ2 2024 Total Revenue of $126.7M, a 34% Increase Year-over-Year Galafold &#xAE; Q2 Revenue of $110.8M, up 17% Year-over-Year Pombiliti &#xAE; + Opfolda &#xAE; Q2 Revenue of $15.9M, up 44% from Q1 2024 ...FOLD - Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities